Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
1(25%)
Results Posted
67%(2 trials)

Phase Distribution

Ph phase_3
1
25%
Ph phase_4
2
50%

Phase Distribution

0

Early Stage

0

Mid Stage

3

Late Stage

Phase Distribution3 total trials
Phase 3Large-scale testing
1(33.3%)
Phase 4Post-market surveillance
2(66.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(3)

Detailed Status

Completed3
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 31 (33.3%)
Phase 42 (66.7%)

Trials by Status

recruiting125%
completed375%

Recent Activity

1 active trials
Showing 4 of 4
recruitingphase_4

Clinical and Biomarker Effects of Depot Medroxyprogesterone Acetate in Females With Sickle Cell Disease

NCT06665997
completed

Contraceptive Hormones, Immunity, and Microbiome Evaluation

NCT03660046
completedphase_4

Impact of Hormonal Contraception on HIV Acquisition and Transmission Risk

NCT02357368
completedphase_3

Drug Exposure and Depot Medroxyprogesterone Acetate (DMPA) in Adolescent Subjects

NCT01461824

Clinical Trials (4)

Showing 4 of 4 trials
NCT06665997Phase 4

Clinical and Biomarker Effects of Depot Medroxyprogesterone Acetate in Females With Sickle Cell Disease

Recruiting
NCT03660046

Contraceptive Hormones, Immunity, and Microbiome Evaluation

Completed
NCT02357368Phase 4

Impact of Hormonal Contraception on HIV Acquisition and Transmission Risk

Completed
NCT01461824Phase 3

Drug Exposure and Depot Medroxyprogesterone Acetate (DMPA) in Adolescent Subjects

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4